Maze Therapeutics
MAZEMaze Therapeutics is a clinical-stage biopharmaceutical company that utilizes its proprietary Compass platform to develop small molecule precision medicines for kidney and metabolic diseases.
Earnings
Next report
Nov 5, 2026 (in 2 months)Valuation & ratios
Segments
By geography
Competitors
By market cap
By revenue growth
Profile
Maze Therapeutics is a clinical-stage biopharmaceutical company that utilizes its proprietary Compass platform to develop small molecule precision medicines for kidney and metabolic diseases. By integrating human genetics and variant functionalization, the company identifies genetic drivers of disease to design therapies that mimic protective variants or correct toxic ones. Their lead programs focus on genetically defined subsets of chronic kidney disease and inherited metabolic disorders.
Maze is a clinical-stage developer of precision medicines leveraging a proprietary functional genomics platform to target genetically validated pathways in kidney and metabolic health.
FAQ
- What is Maze Therapeutics's market cap?
- Maze Therapeutics (MAZE) has a market capitalization of $1.3B and trades on NASDAQ.
- Who are Maze Therapeutics's competitors?
- Maze Therapeutics's key competitors include Vertex Pharmaceuticals, Compass Therapeutics, Inc. Common Stock, Curis Inc, and others. These companies compete in similar markets and product categories.
- Who does Maze Therapeutics partner with?
- Maze Therapeutics's notable partners include Shionogi & Co., Ltd, Neurocrine Biosciences, Inc., Trace Neuroscience, Inc., and others.
- What subsidiaries does Maze Therapeutics have?
- Maze Therapeutics's subsidiaries include Broadwing.
- Where is Maze Therapeutics headquartered?
- Maze Therapeutics is headquartered in United States of America. It has been publicly traded since 2025.